New CEO to Swedish Tillotts Pharma

The Swiss company Tillotts Pharma's newly established Swedish organisation has appointed a CEO from Bayer Scandinavia.
The Swiss biopharmaceutical company Tillotts Pharma has recently entered Sweden, by opening an office in Stockholm under private management. Through the creation of this new Swedish company the company has appointed Mattias Norrman as CEO. Mattias Norrman has previously worked at Bayer Scandinavia, in a chief position.

Tillotts Pharma is focused on gastroenterology and stand behind the drug Asacol, used against intestine inflammations. The drug’s turnover in the Nordic countries is almost SEK 170 million. The new Nordic Tillotts Pharma will continue to focus on Asacol.
Kommentera en artikel
Utvalda artiklar


Sänd till en kollega